Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, October 31, 2022
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Clinical Trials, Webcast, Company, PIN, Investor, Medication, Alopecia areata, CNCE, NASDAQ, Pharmaceutical industry
Geotags: 
UNITED STATES, NORTH AMERICA, MASSACHUSETTS
⚠ partially generated by AI ↴
Organisation: 
CONCERT PHARMACEUTICALS, CONCERT PHARMACEUTICALS, INC., Concert
Stock Symbol: 
NASDAQ:CNCE
Summary
Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open.
  • ET to discuss its third quarter 2022 financial results and provide a business update.
  • Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543) , a novel, deuterated, oral JAK1/2 inhibitor.
  • Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease.


Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provide a business update.

To join the live call to ask questions, please register here. A dial in and unique PIN will be provided to join the call.

An audio-only webcast of the call may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for three months.

About Concert

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease. The Company is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter, Instagram or LinkedIn.

Copyright: 
Copyright Business Wire 2022